The Roskamp Institute publish data suggesting that plant pigments might be helpful in Alzheimer’s disease.

A team of researchers at the Roskamp Institute in Sarasota, Florida lead by Drs. Daniel Paris and Michael Mullan have shown that plant pigments known as flavonoids are able to reduce the toxic amyloid peptide that accumulates in Alzheimer’s disease. Flavonoids are a family of plant pigments responsible for the color of petals of many plants. it has long been suggested that flavonoids may have potential therapeutic effects. Cell based studies have previously shown that they can exert anti-alergic, anti-inflammatory, anti-microbial, and potentially anti-cancer effects. Flavonoids are taken in quite large amounts by animals and are included in some human diet. The team at the Roskamp Institute are interested in lowering the production of amyloid the Alzheimer peptide associated with the disease. Drs. Paris, Mullan and colleagues have showed that in cell culture flavonoids can lower the production of amyloid. This appears to occur via the inhibition of the enzyme which makes amyloid. This enzyme, called NFkB, is ubiquitously expressed in cells including neurons. The research suggests that some invivo (animal testing) of flavonoids might be the next step to determine whether they have a potential role in treating Alzheimer’s.

The Roskamp Institute is a not-for-profit, stand alone, research institute located in Sarasota, Florida. Under the leadership of Drs. Michael Mullan and Fiona Crawford, the institute has focused its activities on developing new treatments for Alzheimer’s disease. The paper on flavonoids and Alzheimer’s Abeta was published in the Journal of Bioinformation in 2011.

Bioinformation. 2011;6(6):229-36. Epub 2011 Jun 6.
Flavonoids lower Alzheimer’s Aβ production via an NF-KB dependent mechanism. Paris D, Mathura V, Ait-Ghezala G, Beaulieu-Abdelahad D, Patel N, Bachmeier C, Mullan M.

For more information please visit:

<a href=’‘></a>
<a href=’‘></a>

<a href=’‘></a>

michael mullan, alzheimer, mullan alzheimer, mullan roskamp, roskamp institute, amyloid